Leadoptik

Cleared by FDA, LEADOPTIK's Last Inch Assessment (LIA) platform transforms biopsy into a digital tissue-intelligence workflow. It integrates proprietary depth imaging technology directly into a standard biopsy needle, enabling instant, on-site, in-vivo tissue characterization without delay. A compact console provides depth-resolved imaging and data capture for AI-driven classification, creating a bridge between navigation and pathology. With the core optical hardware now validated, LIA’s roadmap centers on software development and AI-based tissue characterization, turning imaging data into actionable insights during the procedure.